Project Grant K99CA296769
Award Date
4/1/25
Completion Date
3/31/27
Dollars Obligated
$176K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) is funding a research project to investigate mechanisms of immune therapy resistance. The $620,820 award to The General Hospital Corporation (Massachusetts General Hospital) supports studies to: 1) understand the molecular regulation and transcriptional effects of the CREB5 transcription factor, which was identified as a driver of immune evasion; 2) examine CREB5-interacting proteins...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides $701,408 to The General Hospital Corporation (Massachusetts General Hospital) to conduct research aimed at elucidating resistance mechanisms and enhancing response to immune checkpoint blockade in central nervous system (CNS) metastases from breast cancer. The project involves several ongoing Phase II clinical trials exploring the use of newly...
The National Institutes of Health's National Cancer Institute awarded $331,085.91 under the Cancer Research Manpower federal grant program (CFDA 93.398) to Brigham & Women's Hospital Inc. on February 1, 2021 for completion by September 30, 2022. The project grant funding will support research investigating the role of cellular senescence in chemotherapy-related cognitive impairment and the contribution of microglia to chemotherapy-induced senescence in the brain. Specifically, the grantee...
This $127,049.00 federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) aims to define the functional and spatial properties of tumor-specific tumor-infiltrating CD8 T cells. Specifically, the project will:
Generate patient-derived xenograft (PDX) murine models of 3 melanoma patient tumors to test the required diversity of T cell receptors (TCRs) from tumor-infiltrating T cells needed to exert immune pressure on a heterogeneous tumor like...
The National Cancer Institute (NCI) awarded a $101,856 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to The Trustees of Columbia University in the City of New York to support research on the impact of genomic variants on T cell anti-tumor activity. The grant funding will enable in-depth mechanistic and in vivo functional studies of single-nucleotide variants in genes like PIK3CD and PPP3CA, which have been found to enhance multiple hallmarks of T cell activity and...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $196,029 to the University of Massachusetts Medical School (UMass Medical) to support research aimed at deciphering the immune evasion mechanisms in cancers harboring mutations in the isocitrate dehydrogenase 1 (mIDH1) gene. The funded work will focus on two key objectives: 1) Elucidating the role of viral mimicry in the response to mIDH1 inhibition, and 2) Exploring the contribution...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $1,569,158 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to investigate the role of the APOBEC3A (A3A) enzyme in driving cancer evolution and drug resistance.
The key objectives are to: 1) Determine if A3A expression is upregulated during targeted cancer therapy, leading to drug-resistant mutations; 2)...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) provides $297,728 to The General Hospital Corporation (Massachusetts General Hospital) to conduct research on enhancing the antitumor activity of CD70 chimeric antigen receptor (CAR) T cells through targeted delivery of a VEGF-blocking single-chain variable fragment (scFv) in renal cell carcinoma. The key objectives are to determine the effect of locally secreted VEGF blockade on CD70...
This Project Grant, awarded by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program, provides $208,415.00 in funding to Duke University to conduct research on the mechanisms of macrophage-mediated immune evasion in residual tumors. The research aims to investigate how residual cancer cells evade the immune system, specifically by upregulating "don't eat me" markers like CD47, following treatment with oncogene-targeted therapies. The project...
This federal Cooperative Agreement award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $797,986 of funding to The General Hospital Corporation (Massachusetts General Hospital) to investigate immune mechanisms that can prevent breast cancer development in BRCA mutation carriers.
The key objectives are to: (1) determine the immune factors in BRCA mutant breast glands that induce anti-tumor immune responses, (2)...